Back to search results

Laser Interstitial Thermal Therapy for Low-Grade Glioma in Young People

This study is looking at how well Laser Interstitial Thermal Therapy (LITT) works for young people (ages 2 to 25) who have low-grade glioma (a type of brain tumor) that has come back or gotten worse after previous treatments. LITT is a targeted therapy that uses heat from a laser to destroy tumor cells. The main goal is to see what percentage of participants do not have their tumor grow or spread for at least 15 months after LITT. You would have an MRI scan and complete questionnaires as part of the study. The study is currently unclear on its recruitment status.

Study design
This is an interventional study with a planned enrollment of 40 participants. The phase of the study is not specified.
What's involved
Participants will undergo a single imaging procedure (MRI) and complete questionnaires. The duration of participation is up to 15 months for the primary endpoint.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for up to 15 months to measure progression-free survival, and potentially longer for other exploratory outcomes like seizure frequency (1- and 2-years).

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07506239

Efficacy of Laser Interstitial Thermal Therapy in Young Persons With Low-grade Glioma

Recruiting
NAAges 2–25InterventionalTreatment
University of California, San Francisco
~40 participants
Updated 2026-04-01 on ClinicalTrials.gov
What's tested:Laser Interstitial Thermal Therapy (LITT)Magnetic resonance imaging (MRI)Questionnaires

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Proportion of participants with Progression-free Survival (PFS)
Measured over up to 15 months

Conditions

Low-grade Glioma
Recurrent Low Grade Glioma
Low Grade Glioma of Brain
Pediatric Cancer

Explore related trials

Low Grade Glioma

NCT07506239

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • University of California, San Francisco

    San Francisco, Californiastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Sabine Mueller, MD, PhD · PRINCIPAL_INVESTIGATOR · University of California, San Francisco
  • Margaret Shatara · STUDY_CHAIR · Children's Minnesota

Who to contact

PNOC Operations Office
[email protected]
415-502-1600
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participants must have recurrent or progressive pediatric LGG who have received at least one prior treatment. Prior treatment may include surgery alone and/or systemic therapy.
Participants must have histologically confirmed LGG that is recurrent or progressive after prior treatment and determined to be a candidate for LITT by central review. All patients will undergo central review prior to LITT. Any number of previous recurrences are permissible provided the participant meets other enrollment criteria.
Tumor size: up to 5 cm in largest dimension not including any cystic component. Larger tumors will need to be discussed with the study team. Additional adjunctive interventions such as cyst aspiration prior to or concurrent with a LITT procedure is allowed at the treating surgeon's discretion.
Suprasellar gliomas not arising from the optic pathway are eligible.
Multifocal or metastatic LGGs are eligible, provided that the growing lesions are suitable for LITT.
Exophytic brainstem lesions, which are more accessible and present a lower risk, may be eligible for LITT.
A patient with stable leptomeningeal disease and a separate growing lesion suitable for LITT is eligible for the study.
Prior Therapy: Participants may have had LITT for other medical indications, provided that the lesion being considered for this study has not previously undergone LITT, except for patients who have received LITT for an intracranial lesion that has shown progression post-LITT beyond 15 months would be eligible.
Participants must have fully recovered from the acute toxic effects of all prior chemotherapy or targeted therapy prior to entering this study and would be eligible for surgical intervention per institutional guidelines.
Bevacizumab: participants must have received last dose \> 21 days prior to study registration.
Participants must have had chemotherapy \> 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to registration.
Participants must be at least 7 days since the completion of therapy with a biologic or small molecule agent. For any agent with known adverse events that can occur beyond 7 days after administration, the period prior to enrollment must be beyond the time during which adverse events are known to occur. Such patients should also be discussed with study chairs.
Radiation:
Had their last fraction of local irradiation or focal radiosurgery to primary tumor ≥12 weeks prior to registration.
Had their last fraction of craniospinal irradiation or total body irradiation ≥ 12 weeks prior to registration
Age \>= 2 years to \<= 25 years of age
Performance Score: Karnofsky ≥ 50 for participants \> 16 years of age and Lansky ≥ 50 for participants ≤ 16 years of age. Participants who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.
Corticosteroids: Participants who are receiving dexamethasone must be on a stable or decreasing dose for at least 1 week prior to registration.
Patients must be surgically eligible per institutional standards.
Patients must co-enroll to Pediatric Neuro-oncology Consortium (PNOC) COMP if PNOC COMP is open to accrual at the enrolling institution.
A legal parent/guardian or patient must be able to understand, and willing to sign, a written informed consent and assent document, as appropriate.

Exclusion

Any contraindication to the use of LITT, such as but not limited to:
Optic pathway gliomas
Spinal tumors
Brainstem Lesions: Infiltrative brainstem lesions are excluded. However, exophytic brainstem lesions, which are more accessible and present a lower risk, may be eligible for LITT.
Any lesion/location determined by central review to be contraindicated for LITT.
The presence of uncontrolled leptomeningeal disease or extracranial disease including:
Evidence of untreated obstructive hydrocephalus or mass effect causing \>10 millimeter (mm) midline shift
Presence of symptomatic intratumoral hemorrhage (Grade 3 \& 4). Intratumoral hemorrhage grade 2 needs to be discussed with study team.
Participants who are receiving any other investigational agents.
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection.

What this trial measures

  • Proportion of participants with Progression-free Survival (PFS)up to 15 months

    PFS is defined as proportion of participants who do not experience further disease progression at 15 months following and assessed by MRI according to Response Assessment in Pediatric Neuro-Oncology (RAPNO) criteria.